🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseEfinopegdutide MASH data — July 2024 Page 4

Efinopegdutide MASH data — July 2024

KarenAZ_mom Thu, May 30, 2024 at 2:14 PM 39 replies 2,830 viewsPage 4 of 8
JenPlateau
Member
234
890
Nov 2024
Missouri
Jun 8, 2024 at 3:57 PM#16

Adding the clinical framing, because it changes how the question reads. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.

2 0HPLC_Greg, LibrarianMeg
Reply Quote Save Share Report
nick_newbie
New Member
18
56
Jun 2026
Virginia
Online
Jun 9, 2024 at 10:24 PM#17

Following on from wanda_boise — and this may be the naive question:

What would you measure differently if you were starting again?

Last edited: Jun 10, 2024 at 1:24 AM
3 1dan_philly, MeganSA_TX, LarryQC_SD
Reply Quote Save Share Report
ZaraB_AL
Member
456
1,678
Jan 2025
Alabama
Jun 11, 2024 at 4:50 AM#18
JenPlateau said:
Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…

I read this differently from JenPlateau, on substance rather than tone. This treats a plausible mechanism as a demonstrated one. Plausible is where you start looking, not where you stop.

4 2TirzTom, TrialTracker_MD, JennaRN and 1 other
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
emily_PDX
Member
245
1,123
Nov 2024
Portland, OR
Jun 12, 2024 at 11:15 AM#19
JenPlateau said:
Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…

JenPlateau has the substance of this right. The condition it depends on is worth stating. Yes, and the corollary is less popular: if the reasoning holds, it also holds where it produces an answer we do not like.

5 3Dr.KarenChen, Dr.NateNeph, PharmD_Rodriguez and 2 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jun 13, 2024 at 5:40 PM#20

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful.

27 0PurityPaulOR, MaxMetOK, MounjBrad and 24 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register